Mosaic Biosciences Expands Leadership to Enhance Drug Discovery
Mosaic Biosciences has made significant strides in its mission to provide innovative drug discovery solutions. Recently, the organization announced the addition of three key executives who are set to play pivotal roles in the company’s future. The newly appointed leaders are Luyuan Mendhi, MBA, as Chief Financial Officer, Tracey Mullen, MBA, as Chief Strategy Officer, and Christilyn Graff, PhD, as Senior Vice President, Head of Research.
Welcoming New Leaders to the Team
Eric Furfine, co-CEO and Chief Scientific Officer of Mosaic Biosciences, expressed his enthusiasm about the new appointments, stating, “We are thrilled to welcome Luyuan, Tracey, and Christilyn to the Mosaic executive team. Their leadership, expertise, and vision align with our mission to deliver best-in-class drug discovery solutions to our partners.” This robust expansion demonstrates the company's commitment to innovation in the rapidly evolving biopharma industry.
Growth Through Expertise
The introduction of these leaders signifies a key moment in Mosaic's growth trajectory, reinforcing its dedication to providing exceptional research and discovery services. The biopharma landscape is increasingly dynamic, and with these seasoned professionals on board, Mosaic is well-equipped to respond to the growing demands for comprehensive drug discovery services.
The New Executive Team
Luyuan Mendhi comes to Mosaic with a wealth of experience in biopharma finance, previously serving as VP, Head of Finance at Alloy Therapeutics and director at Novartis. With her background managing substantial budgets and strategic projects, she is poised to steer Mosaic’s financial operations effectively. Notably, Luyuan played a significant role in the successful launch of Scemblix for chronic myeloid leukemia, underscoring her capability in driving impactful financial decisions.
Tracey Mullen brings extensive experience in drug discovery and biopharma services commercial development to her role. She formerly held the position of Senior Vice President of Biopharma at Twist Biosciences, where she oversaw the integrated Biopharma Solutions unit after the acquisition of Abveris. Tracey’s success as the CEO of Abveris, where she built a leading antibody discovery platform, demonstrates her strategic insight and innovative thinking.
Christilyn Graff, serving as Senior Vice President and Head of Research, has over two decades of experience in biologics drug discovery. Her previous role as Senior Director at Biogen involved expanding the early biologics portfolio and optimizing research and development processes. With a focus on integrating new technologies and data methodologies, Christilyn is committed to driving excellence within Mosaic’s research framework.
About Mosaic Biosciences
Mosaic Biosciences is revolutionizing drug discovery by offering a fully integrated platform tailored for biotech, biopharma, and academic institutions. The company specializes in the discovery, characterization, and optimization of protein therapeutics, providing essential screening and advanced cell-based assays from the outset of the drug discovery process. This comprehensive approach ensures that all potential therapeutics are rigorously evaluated for their effectiveness in real-world applications.
Furthermore, Mosaic facilitates rapid animal pharmacokinetic and pharmacodynamic studies, which aid in swift decision-making for researching viable therapeutic breakthroughs. The organization’s multidisciplinary team leverages cutting-edge proprietary tools and data-driven methodologies, working collaboratively with partners to deliver top-tier solutions for contemporary drug discovery challenges.
With a commitment to enhancing human health, Mosaic Biosciences stands as a pivotal player in drug discovery, empowering its partners toward efficient and effective therapeutic advancements.
Frequently Asked Questions
What recent changes have occurred in Mosaic Biosciences' leadership?
Mosaic Biosciences has expanded its executive leadership team with the addition of Luyuan Mendhi, Tracey Mullen, and Christilyn Graff, enhancing its strategic vision.
What previous roles did the new executives hold?
Luyuan Mendhi was VP, Head of Finance at Alloy Therapeutics, Tracey Mullen was the CEO of Abveris, and Christilyn Graff was a Senior Director at Biogen.
How does Mosaic Biosciences support drug discovery?
Mosaic provides a fully integrated platform that offers screening, characterization, and optimization services for protein therapeutics, ensuring efficient evaluation of therapeutics.
What is the impact of the new leadership team?
The new leadership team enhances Mosaic's capability to innovate and meet the evolving needs of the biopharma industry, ensuring better service delivery.
What is Mosaic Biosciences' commitment to its partners?
Mosaic is dedicated to advancing human health by collaborating closely with partners and providing valuable insights and solutions in drug discovery processes.
